Weekly Subcutaneous VK2735 , a GIP / GLP ‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study
Authors' conclusion
All subcutaneous doses of VK2735 significantly reduced body weight. The AE profile of VK2735 was primarily gastrointestinal, with decreased reported frequency upon continued use.
Study context
- Population
- Adults with obesity or overweight and ≥1 weight-related comorbidity; DM excluded
- Comparison
- Weekly subcutaneous VK2735 vs placebo
- Placebon = 34reference
- Primary endpoint
- Percent change from baseline in body weight
- Follow-up
- Week 13
Methodological detailsphase 2, double-blind, placebo-controlled, dose-ranging, Conducted August 2023 to February 2024
- Phase 2
- Double-blind
- Placebo-controlled
- Dose-ranging
- Conducted August 2023 to February 2024
Primary result
As reported in the abstract
Mean weight reduction
| Group | Value | Weight reduction (kg) |
|---|---|---|
| VK2735 2.5 mg | mean 9.1% | 9.2 kg |
| VK2735 15 mg | mean 14.7% | 14.6 kg |
| Placebo | 1.7% | 1.8 kg |
Value
VK2735 2.5 mgmean 9.1%
VK2735 15 mgmean 14.7%
Placebo1.7%
Weight reduction (kg)
VK2735 2.5 mg9.2 kg
VK2735 15 mg14.6 kg
Placebo1.8 kg
- Active-dose range of mean weight reduction
- 9.2 kg (2.5 mg) to 14.6 kg (15 mg)
Secondary outcomes
- ≥5% weight reduction — Placebo
- 12%
- ≥5% weight reduction: VK2735 (all active doses) 93%
- ≥5% weight reduction: 130/140 active; 4/34 placebo
Safety
Adverse events
- Common adverse events (AEs) were gastrointestinal, decreasing in reported frequency after dose titration to steady state
Original publication
Weekly Subcutaneous VK2735 , a GIP / GLP ‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study. Obesity (Silver Spring). Published 8 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →